At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Azacitidinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
In Brief
A Phase 2 clinical trial evaluating Azacitidine for Myelodysplastic Syndromes. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The primary endpoint of this study is to estimate morphologic complete remission rate. Estimation of response rate is also a secondary objection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndromes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedOct 2006
Primary CompletionAug 2008
Study CompletionMar 2010
TodayJul 2026
First PostedOct 6, 2006
Enrollment StartAug 1, 2006
Primary CompletionAug 1, 2008
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.7 years ago
Interventions
Azacitidinedrug